Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

So Heun Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4628-2894; OpenAlex author ID A5070468382. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers

Papers 5

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-19841-5↗
  3. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Co-author DOI 10.1245/s10434-026-19926-1↗
  4. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  5. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changhoon Yoo · 5 shared papers, 2022–2026 · strength 0.95
  2. José Oberholzer · 3 shared papers, 2026 · strength 0.69
  3. Ning Pu · 3 shared papers, 2026 · strength 0.69
  4. Dilmurodjon Eshmuminov · 3 shared papers, 2026 · strength 0.69
  5. Víctor López‐López · 3 shared papers, 2026 · strength 0.69
  6. Michael C. Frey · 3 shared papers, 2026 · strength 0.69
  7. Ralph Fritsch · 3 shared papers, 2026 · strength 0.69
  8. Bradley Norman Reames · 2 shared papers, 2026 · strength 0.50
  9. Haleh Amirian · 2 shared papers, 2026 · strength 0.50
  10. Chunmeng Zhang · 2 shared papers, 2026 · strength 0.50
  11. Jashodeep Datta · 2 shared papers, 2026 · strength 0.50
  12. Ki Byung Song · 2 shared papers, 2022–2023 · strength 0.26
  13. Kyu‐pyo Kim · 2 shared papers, 2022–2023 · strength 0.26
  14. Do Hyun Park · 2 shared papers, 2022–2023 · strength 0.26
  15. Jin‐hong Park · 2 shared papers, 2022–2023 · strength 0.26
  16. Dae Wook Hwang · 2 shared papers, 2022–2023 · strength 0.26
  17. Tae Jun Song · 2 shared papers, 2022–2023 · strength 0.26
  18. Woohyung Lee · 2 shared papers, 2022–2023 · strength 0.26
  19. Bong Jun Kwak · 2 shared papers, 2022–2023 · strength 0.26
  20. Dong Wan Seo · 2 shared papers, 2022–2023 · strength 0.26
  21. Baek‐Yeol Ryoo · 2 shared papers, 2022–2023 · strength 0.26
  22. Sang Soo Lee · 2 shared papers, 2022–2023 · strength 0.26
  23. Dongwook Oh · 2 shared papers, 2022–2023 · strength 0.26
  24. Song Cheol Kim · 2 shared papers, 2022–2023 · strength 0.26
  25. Syed A. Ahmad · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.